ASCO 2014 – Lung Cancer

Gefitinib Plus Carboplatin/Pemetrexed as First-Line Therapy of EGFR+ NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent

First-Line Nivolumab Monotherapy in Advanced NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent

Results from the ARCHER 1009 Study: Dacomitinib Versus Erlotinib for Second-/Third-Line Therapy of Locally Advanced or Metastatic NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent

Results from PROFILE 1014: First-Line Crizotinib Versus Pemetrexed-Platinum in ALK+ NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent

Erlotinib Plus Bevacizumab as First-Line Treatment for EGFR+, Advanced NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent

A Mutant-Selective EGFR Inhibitor in NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent

Ceritinib in Advanced ALK-Rearranged NSCLC: Results from the ASCEND-1 Trial

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent

Docetaxel and Cisplatin Plus Chemoradiation in Inoperable Stage III NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent

Results from RADIANT: Adjuvant Erlotinib in NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent

Breaking News from the REVEL Study in NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent

Page 1 of 3

1
2
3